XML 62 R50.htm IDEA: XBRL DOCUMENT v3.23.3
Deferred Royalty Obligation related to the Sale of Future Royalties - Schedule of Royalty Obligation transaction (Details)
$ in Thousands
 9 Months Ended
Sep. 30, 2023
USD ($)
Deferred Royalty Obligation [Line Items]  
Deferred royalty obligation related to the sale of future Vaxcyte royalties, net $ 142,763
Vaxcyte, Inc.  
Deferred Royalty Obligation [Line Items]  
Proceeds from sale of future Vaxcyte royalties 140,000
Issuance costs (3,792)
Non-cash interest expense associated with the sale of future Vaxcyte royalties 6,378
Amortization of issuance costs 177
Deferred royalty obligation related to the sale of future Vaxcyte royalties, net $ 142,763